Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J]. LANCET, 2005, 365 (9464) : 1054 - 1061

[2] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J]. NATURE, 2005, 434 (7037) : 1144 - 1148

[3] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J]. BLOOD, 2005, 106 (06) : 2162 - 2168

[4] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790

[5] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J]. CANCER CELL, 2005, 7 (04) : 387 - 397

[6] Pearson TC, 1996, LEUKEMIA LYMPHOMA, V22, P87

[7] Pearson Thomas C., 2000, Hematology Am Soc Hematol Educ Program, P51

[8] PIERRE R, 2001, WHO CLASSIFICATION T, P32

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J]. LANCET, 2005, 365 (9464) : 1054 - 1061

[2] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J]. NATURE, 2005, 434 (7037) : 1144 - 1148

[3] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J]. BLOOD, 2005, 106 (06) : 2162 - 2168

[4] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790

[5] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J]. CANCER CELL, 2005, 7 (04) : 387 - 397

[6] Pearson TC, 1996, LEUKEMIA LYMPHOMA, V22, P87

[7] Pearson Thomas C., 2000, Hematology Am Soc Hematol Educ Program, P51

[8] PIERRE R, 2001, WHO CLASSIFICATION T, P32